-

Medable to Present at Morgan Stanley Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading AI technology platform provider for clinical research, today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the Morgan Stanley Global Healthcare Conference in New York City. The presentation will take place on Tuesday, September 9th 7:45 AM Eastern Time.

About Medable

Medable, a Software as a Service (SaaS) cloud platform, is revolutionizing clinical drug development. Our AI-driven platform, including Agent Studio, enhances speed, scale, and patient access in clinical research. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com

Industry:

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI
Release Versions
English

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com

Social Media Profiles
Medable on LinkedIn
More News From Medable Inc.

MRCT Center and Medable Launch New Resources for Investigator Oversight in Decentralized Clinical Trials

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of agentic clinical development technology, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) today announced new resources for sponsors and investigators. The tools will be available beginning September 23, 2026. The resources and practical tools help sponsors and investigators determine which trial activities can appropriately take place closer to participants and establi...

Medable and ICON Exceed Patient eConsent Adoption Goals for Women’s Health Study on Menopause

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced the impact of its Total Consent solution in a U.S women’s health study on menopause managed by ICON plc. Beating expectations, more than 85% of trial participants, or 1,044 out of 1,222, consented using Medable’s enhanced eConsent technology. And, 18 sites achieved 100% eConsent adoption among participants, while the top-enrolling site achieved 91% adoption. With...

New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment. The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value and experience d...
Back to Newsroom